Global Search | Novartis

Hide Filters

Showing 50 results

Press release / Oct 08, 2018

Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients

There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of…
Press release / Nov 29, 2018

Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe

Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-free…
Press release / May 12, 2018

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)[1] In a…
Press release / Sep 05, 2017

Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS

Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a There is a significant unmet…
Press release / Sep 17, 2016

Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients

EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary…
Press release / Mar 23, 2018

Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS

EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate…
Press release / Oct 28, 2017

Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a

PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a Currently there are no specifically approved disease…
Press release / Oct 25, 2017

Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS

Full data from the pivotal Phase III PARADIGMS study of Gilenya® (fingolimod) in pediatric MS will be presented for the first time With 54 accepted abstracts, Novartis presence spans from…
Press release / Sep 12, 2018

Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS

Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects…
Press release / Apr 24, 2017

Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS

Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the…